Related Experiment Videos

Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic

Michelle M Le Beau1, Sheila Bitts, Elizabeth M Davis

  • 1Section of Hematology/Oncology, University of Chicago, Illinois 60637, USA. mlebeau@medicine.bsd.uchicago.edu

Blood
|April 4, 2002
PubMed

Insights

Genetic alterations cooperate with the PML-RARA fusion gene to drive acute promyelocytic leukemia (APL) development. Secondary mutations in mouse models partially mirror cytogenetic abnormalities observed in human APL patients.

Area of Science:

  • Hematology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Acute promyelocytic leukemia (APL) is defined by the t(15;17) translocation, creating the PML-RARA fusion gene.
  • Previous research established that PML-RARA expression in murine granulocyte precursors can initiate leukemia, but requires additional genetic changes.

Purpose of the Study:

  • To identify genetic alterations that cooperate with PML-RARA in leukemogenesis.
  • To compare genetic changes in murine models with human APL cytogenetics.

Main Methods:

  • Spectral karyotyping analysis of myeloid leukemias in PML-RARA transgenic mice.
  • Analysis of secondary genetic abnormalities in a cohort of 965 human APL patients.

Main Results:

  • Clonal abnormalities were detected in 95% of murine leukemias, with common numerical changes including +15, loss of sex chromosome, and +8.
  • In human APL, secondary abnormalities occurred in 38% of patients, with +8/trisomy 8q and ider(17) being most frequent.
  • Gain of 8q24 in human leukemia is syntenic to mouse chromosome 15, suggesting conserved mechanisms.

Conclusions:

  • PML-RARA-initiated murine leukemia exhibits a specific spectrum of genetic changes.
  • These secondary mutations in mice partially recapitulate the cytogenetic abnormalities found in human APL.
  • The findings highlight conserved genetic cooperation in APL pathogenesis across species.

Related Concept Videos